



Pfizer-BioNTech COVID-19 Vaccine: US Distribution Fact sheet

Overview:

- Pfizer is a proven, reliable vaccine producer, supplying vaccines to more than 165 countries – even before the COVID-19 pandemic. In fact, Pfizer is one of the largest sterile injectables suppliers in the world.
- This proven track record gives us the ability to quickly scale, manufacture and distribute large quantities of the COVID-19 vaccine, leveraging multiple Pfizer-owned sites in the United States, as well as our global supply chain and support from our many partners around the world.
- Pfizer successfully manufactured more than 3 billion doses of the Pfizer-BioNTech COVID-19 Vaccine in 2021 and expects to manufacture 4 billion doses in 2022, including all approved and / or authorized formulations.
- As of March 2022, more than 3.2bn doses have been shipped to every corner of the world.

Distribution:

- Our distribution is built on a flexible, just-in-time system, which ships the frozen vials direct to the point of vaccination.
- We have developed and implemented detailed logistical plans and tools to support effective vaccine transport and storage innovations to be fit for purpose for the range of locations where vaccinations take place.
- This includes developing temperature-controlled thermal shippers that utilize dry ice to maintain recommended storage temperature and a GPS tracker for 24 hour location and temperature monitoring.
- We are utilizing road and air modes of transportation via our main carrier partners. Through this approach, we are able to deliver from our Pfizer sites directly to POU within a day or two in the U.S.

- In the U.S., our distribution is direct from our manufacturing facility in Kalamazoo, Michigan, to the point of use (POU), or from our distribution center in Pleasant Prairie, Wisconsin, as a supplemental location.
- Since the first authorization was granted, Pfizer has been working closely with the U.S. government, including state officials, on vaccine distribution, and we are very grateful for their partnership.
- Pfizer has a 99% success rate in getting shippers containing the Pfizer-BioNTech COVID-19 Vaccine to their destination within all prespecified parameters.

Storage:

- Pfizer now provides two different sizes of thermal shipper and pack sizes depending on the formulation.
 - For example, to fit the end user's need including more convenient storage and smaller packaging, the pediatric doses of the COVID-19 vaccine are available in a 10 vial-pack configuration with the ability to order 1 to 10 packs (10 to 100 vials). Each vial contains 10 doses instead of 6.
- Once a POU receives a thermal shipper with the Pfizer-BioNTech COVID-19 Vaccine, there are multiple options for storage, allowing maximum flexibility.
 - For example, the Pfizer-BioNTech COVID-19 adult (12+) vaccine formulation:
 - Ultra-low-temperature freezers, which are commercially available and can extend shelf life for up to nine months.
 - The shippers, in which the Pfizer-BioNTech COVID-19 Vaccine doses arrive, can be used as temporary storage units by refilling with dry ice every five days for up to 30 days of storage.
 - The vaccine can also be stored for up to one month (31 days) at refrigerated 2-8°C conditions.
- We are working hard to continue to gather and assess stability data to support even more flexible storage conditions in the future.

The full details on how to store and administer all authorized versions of the Pfizer's COVID-19 vaccine can be found on the FDA website.

For more information on Pfizer's efforts to manufacture and distribute the COVID-19 vaccine visit <https://www.pfizer.com/science/coronavirus/vaccine/manufacturing-and-distribution>

###